Patents by Inventor Robert M. Krug
Robert M. Krug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230372381Abstract: Compositions discussed herein are useful for treating a patient infected with a coronavirus, notably SARS-CoV-2 or COVID-19. The compositions to be administered to an infected patient utilize inhibitors of SARS-CoV-2 papain-like protease (PLpro). Several of these inhibitors include available hepatitis C virus (HCV) drugs that are already FDA-approved. These PLpro inhibitors have been found to be strongly synergistic with inhibitors of SARS-CoV-2 polymerases, such as RNA-dependent RNA polymerase (RdRp). One such polymerase inhibitor, remdesivir, is already in use as an anti-viral treatment of patients with COVID-19. The PLpro inhibitors, including repurposed HCV drugs such as grazoprevir, vaniprevir, and paritaprevir, increase remdesivir's ability to suppress coronavirus replication antiviral activity as much as 10-fold.Type: ApplicationFiled: October 5, 2021Publication date: November 23, 2023Applicant: Rensselaer Polytechnic InstituteInventors: Gaetano Thomas MONTELIONE, Khushboo BAFNA, Robert M. KRUG, Aldolfo GARCIA-SASTRE, Kris WHITE
-
Patent number: 9499595Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.Type: GrantFiled: September 4, 2009Date of Patent: November 22, 2016Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMSInventors: Robert M. Krug, Karen Y. Twu
-
Patent number: 9119810Abstract: Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.Type: GrantFiled: November 17, 2006Date of Patent: September 1, 2015Assignees: Rutgers, The State University of New JerseyInventors: Gaetano T. Montelione, Robert M. Krug, Yin Cuifeng, Ma Lichung
-
Patent number: 9079944Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: November 17, 2014Date of Patent: July 14, 2015Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Publication number: 20150093405Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: November 17, 2014Publication date: April 2, 2015Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 8916519Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: June 24, 2014Date of Patent: December 23, 2014Assignees: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas SystemInventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Publication number: 20140308307Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: June 24, 2014Publication date: October 16, 2014Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 8796008Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF 30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: May 31, 2013Date of Patent: August 5, 2014Assignees: Board of Regents, The University of Texas System, Rutgers, The State University of New JerseyInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Rei-Lin Kuo, Robert M. Krug, Karen Y. Twu
-
Publication number: 20140044745Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: May 31, 2013Publication date: February 13, 2014Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 8455621Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: February 17, 2010Date of Patent: June 4, 2013Assignees: Rutgers, The State University of New Jersery, Board of Regents, The University of Texas SystemInventors: Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo, Gaetano Montelione, Edward Arnold, Kalyan Das, LiChung Ma, Rong Xiao
-
Publication number: 20100291128Abstract: Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.Type: ApplicationFiled: November 17, 2006Publication date: November 18, 2010Inventors: Gaetano T. Montelione, Robert M. Krug, Yin Cuifeng, Ma Linchung
-
Publication number: 20100247569Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: February 17, 2010Publication date: September 30, 2010Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 7709190Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: December 2, 2006Date of Patent: May 4, 2010Assignee: Board of Regents, The University of Texas SystemInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Publication number: 20100107264Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.Type: ApplicationFiled: September 4, 2009Publication date: April 29, 2010Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEMInventors: Robert M. Krug, Karen Y. Twu
-
Publication number: 20100081126Abstract: Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus.Type: ApplicationFiled: September 11, 2009Publication date: April 1, 2010Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Gaetano T. Montelione, Robert M. Krug
-
Patent number: 7601490Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.Type: GrantFiled: December 2, 2006Date of Patent: October 13, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Robert M. Krug, Karen Y. Twu
-
Publication number: 20080234175Abstract: Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus.Type: ApplicationFiled: November 13, 2003Publication date: September 25, 2008Inventors: Gaetano T. Montelione, Robert M. Krug
-
Publication number: 20080108050Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: December 2, 2006Publication date: May 8, 2008Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 5843724Abstract: A chimeric nucleic acid molecule encoding an NS1-Rev fusion protein having Rev function inhibitory activity.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 1998Assignee: Rutgers UniversityInventors: Robert M. Krug, Xiao Yan Qian